SCOT Registry: Small Cell Lung Cancer Treatment and Outcome

CompletedOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Lung Cancer, Small Cell
Interventions
DRUG

HYCAMTIN

Observing patients on HYCAMTIN and other drugs for SCLC.

Trial Locations (61)

1000

GSK Investigational Site, Ljubljana

1130

GSK Investigational Site, Vienna

3233

GSK Investigational Site, Mátraháza

4204

GSK Investigational Site, Golnik

5020

GSK Investigational Site, Salzburg

8000

GSK Investigational Site, Székesfehérvár

10043

GSK Investigational Site, Orbassano (TO)

11619

GSK Investigational Site, Tallinn

14004

GSK Investigational Site, Córdoba

14033

GSK Investigational Site, Caen

20089

GSK Investigational Site, Rozzano (MI)

25030

GSK Investigational Site, Besançon

26789

GSK Investigational Site, Leer

28034

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

33604

GSK Investigational Site, Pessac

34125

GSK Investigational Site, Kassel

34376

GSK Investigational Site, Immenhausen

42271

GSK Investigational Site, Saint-Priest-en-Jarez

42551

GSK Investigational Site, Velbert

43100

GSK Investigational Site, Parma

50009

GSK Investigational Site, Zaragoza

51109

GSK Investigational Site, Cologne

53113

GSK Investigational Site, Bonn

56322

GSK Investigational Site, Lorient

57010

GSK Investigational Site, Thessaloniki

58675

GSK Investigational Site, Hemer

65199

GSK Investigational Site, Wiesbaden

66000

GSK Investigational Site, Perpignan

67091

GSK Investigational Site, Strasbourg

69495

GSK Investigational Site, Pierre-Bénite

71110

GSK Investigational Site, Heraklion, Crete

73100

GSK Investigational Site, Lecce

75020

GSK Investigational Site, Paris

81925

GSK Investigational Site, Munich

83300

GSK Investigational Site, Draguignan

94010

GSK Investigational Site, Créteil

A-8036

GSK Investigational Site, Graz

A-6020

GSK Investigational Site, Innsbruck

625 00

GSK Investigational Site, Brno

305 99

GSK Investigational Site, Pilsen

115 27

GSK Investigational Site, Athens

07100

GSK Investigational Site, Sassari

LT-50009

GSK Investigational Site, Kaunas

LT-92228

GSK Investigational Site, Klaipėda

LT-08660

GSK Investigational Site, Vilnius

LT-08661

GSK Investigational Site, Vilnius

1081 HV

GSK Investigational Site, Amsterdam

4818 CK

GSK Investigational Site, Breda

5623 EJ

GSK Investigational Site, Eindhoven

9713 GZ

GSK Investigational Site, Groningen

66-400

GSK Investigational Site, Gorzów Wielkopolski

41-340

GSK Investigational Site, Głuchołazy

31-115

GSK Investigational Site, Krakow

93-509

GSK Investigational Site, Lodz

20-954

GSK Investigational Site, Lublin

00-909

GSK Investigational Site, Warsaw

463-707

GSK Investigational Site, Seongnam-si, Gyeonggi-do

137-701

GSK Investigational Site, Seoul

442-723

GSK Investigational Site, Suwon, Gyeonggi-do

07014

GSK Investigational Site, Palma de Mallorca

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00997061 - SCOT Registry: Small Cell Lung Cancer Treatment and Outcome | Biotech Hunter | Biotech Hunter